"The second leading cause of death, cancer kills more than half a million people annually, while the cancer drug industry rakes in $100 billion each year while simultaneously causing more cancer. However, this wouldn’t be the case if the cancer treatment industry was more interested in curing and preventing cancer than it is in simply just treating it. The good news is that there are alternatives for preventing and curing cancer, although information on this can be difficult to access, as it’s routinely suppressed by the medical establishment and their paid-for media, who’s not interested in providing “care” unless it’s profitable or generates repeat business. One of the greatest tools in beating cancer is early detection, and no, this does not mean you should include radiological imaging as part of your annual checkup, as that can cause more cancer. However, a little known test called the AMAS test, or the Anti-Malignan Antibody Serum test, is incredibly bene

"A last-chance drug that can lead to an “unprecedented” reduction in lung cancer tumours has become available on the NHS. Tagrisso (osimertinib) was granted a licence only in February and has been hailed as a breakthrough drug by manufacturer AstraZeneca. The once-a-day tablet will be available immediately for patients with non-small-cell lung cancer who have a specific mutation, known as EGFR T790M-positive, that means they have stopped responding to earlier treatments. Experts predict about 300 patients in England and Wales will be eligible for Tagrisso every year. The National Institute for Health and Care Excellence (Nice) has issued final draft guidance that says Tagrisso should be made available through the Cancer Drugs Fund (CDF), after a financial agreement was reached with AstraZeneca. Prof Carole Longson, the director of the health technology evaluation centre at Nice, said the drug was being made available while clinical trials continue to assess its

   Περιστατικό δύο επιτυχημένων κυήσεων στη σειρά μετά από 3 καθ΄έξιν αποβολές ενώ είχαν ένα παιδί    "Στη δημοσίευση των νέων από αναπαραγωγική στις 5-12 επισκέφτηκαν -2015 ζευγάρι (γυναίκα ετών 37 και άνδρας ετών 43) το κέντρο μας το 2013 μετά από δύο παλίνδρομες κυήσεις των δύο προηγούμενων ετών, ενώ είχαν ήδη ένα παιδάκι 5 ετών. Τόσο η γυναίκα όσο και ο άνδρας ήταν σε πολύ καλή κατάσταση και χωρίς προβλήματα υγείας. Αποφασίστηκε να γίνει έλεγχος για θρομβοφιλία τον Απρίλιο του 2013 διότι γινόταν η σύλληψη κανονικά χωρίς κάποιο πρόβλημα με την εμφάνιση καρδιακών παλμών κατά την 6η εβδομάδα της κύησης και στην επανεξέταση της 9ης με 10ης εβδομάδας η καρδιακή λειτουργία είχε σταματήσει χωρίς κάποια εμφανή αιτιολογία από το έμβρυο και έγινε απόξεση. Διερευνήθηκαν οι μοριακές μεταλλάξεις για του παρακάτω παράγοντες «Παράγων V (Leiden_G1691A),Ομοκυστείνη (MTHFR, C677T),Ομοκυστείνη (MTHFR, A1298C), Ινωδογόνο-β (-455 G>A),(HPA-1), Αναστολέας ενεργοποιητή πλασμινο